Screener
Avalo Therapeutics AVTX EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's EBITDA?
- Avalo Therapeutics (AVTX) reported EBITDA of -$31.5M in Q2 2026.
- How has Avalo Therapeutics's EBITDA changed year-over-year?
- Avalo Therapeutics's EBITDA decreased by 64.2% year-over-year, from -$19.18M to -$31.5M.
- What is the long-term trend for Avalo Therapeutics's EBITDA?
- Over 4 years (2021 to 2025), Avalo Therapeutics's EBITDA has grown at a -2.5% compound annual growth rate (CAGR), from -$80.48M to -$72.58M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Avalo Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude